Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1

Author(s):  Zur Eyal

Issue:  May/Jun 2019 - Volume 23, Number 3
View All Articles in Issue

Page(s):  200-207

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Page 1
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Page 2
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Page 3
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Page 4
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Page 5
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Page 6
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Page 7
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Page 8

Download in electronic PDF format for $65

Abstract:  Cutaneous leishmaniasis is the most common form of leishmaniasis with global incidence of about 1.5 million cases annually. The disease is endemic in Israel and caused by two types, Leishmania major and Leishmania tropica. The two types of cutaneous leishmaniasis in Israel are not life threatening, but the multiple skin lesions developed from the contaminated sandfly bites cause significant damage to the quality of life for a few months in patients with Leishmania major and sometimes for more than a year in patients with Leishmania tropica. The disease ends spontaneously, often with disfiguring scars. The aim of the treatment is to significantly shorten the wound-healing process, hopefully with minimal scars and with parasite eradication. Topical treatment for this localized skin disease is very attractive, although only one medication is registered in Israel (15% paromomycin +12% methylbenzethonium chloride ointment), which is for the topical treatment of “Leishmania major.” Relatively low efficacy and significant irritation and pain are two significant disadvantages that characterize this topical medication and could result in failure of the registered treatment. This article, which is presented in 3 parts, discusses three options in the treatment of cutaneous leishmaniasis, 1) amphotericin B liposomal gel and 2) paromomycin sulfate liposomal gel (free of the sensitizing methylbenzethonium chloride), both of which the author considers as efficacious in the treatment of cutaneous leishmaniasis, although to confirm these claims, randomized controlled trials must be conducted, and 3) photodynamic therapy. Most of the reports claim that the photodynamic therapy can achieve results above 90% healing of wounds in a relatively short period of time and with relatively minimal scars. However, a caveat must be held since some of these studies indicate that not all healed wounds become free of the parasite. The daylight option of photodynamic therapy is an interesting modality which abolishes the need for an expensive artificial light source and expensive hospitalization time and enables ambulatory treatment to be efficacious against both types of Leishmania in Israel. Formulations are provided for the three modalities, with the third option being based on 5-aminolevulinic acid hydrochloride as the photosensitizer for this therapy.

Related Keywords: Eyal Zur, BScPharm, RPh, MBA, cutaneous leishmaniasis, zoonoses, sandfly, parasitic infection, topical preparations, local therapy, amphotericin, transdermal administration, formulation, Israel, middle east region, liposomal delivery

Related Categories: DERMATOLOGY, FORMULATIONS, INFECTIOUS DISEASE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1
Zur Eyal
May/Jun 2019
Pg. 200-207

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Zur Eyal
Sep/Oct 2019
Pg. 366-375

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2
Zur Eyal
Jul/Aug 2019
Pg. 288-293

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

PostScription: Compounding in Israel
Zur Eyal
May/Jun 2009
Pg. 262-263

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents
Zur Eyal
Nov/Dec 2012
Pg. 462-469

Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Zur Eyal
Jan/Feb 2019
Pg. 23-31

Bilateral Areolar Hyperpigmentation Following Transdermal Administration of Compounded Hormone Replacement Therapy
Griffee Chris
, Delano Amy
Mar/Apr 2012
Pg. 110-114

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions